Ignite Creation Date:
2025-12-24 @ 9:57 PM
Ignite Modification Date:
2026-02-20 @ 10:57 PM
Study NCT ID:
NCT00637832
Status:
TERMINATED
Last Update Posted:
2022-01-06
First Post:
2008-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma
Sponsor:
University of Southampton
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | recurrent grade 1 follicular lymphoma | View |
| None | recurrent grade 2 follicular lymphoma | View |
| None | recurrent grade 3 follicular lymphoma | View |
| None | contiguous stage II grade 1 follicular lymphoma | View |
| None | contiguous stage II grade 2 follicular lymphoma | View |
| None | contiguous stage II grade 3 follicular lymphoma | View |
| None | noncontiguous stage II grade 1 follicular lymphoma | View |
| None | noncontiguous stage II grade 2 follicular lymphoma | View |
| None | noncontiguous stage II grade 3 follicular lymphoma | View |
| None | stage III grade 1 follicular lymphoma | View |
| None | stage III grade 2 follicular lymphoma | View |
| None | stage III grade 3 follicular lymphoma | View |
| None | stage IV grade 1 follicular lymphoma | View |
| None | stage IV grade 2 follicular lymphoma | View |
| None | stage IV grade 3 follicular lymphoma | View |